In an exciting development for the future of drug discovery, Valo Health has successfully raised $190 million in funding. Valo Health is at the forefront of transforming the pharmaceutical landscape, combining advanced technology with a mission to redefine drug discovery and development through large-scale data analytics and AI-driven computation. By leveraging its innovative Opal Computational Platform™, Valo integrates human-centric data into a cohesive architecture that streamlines the entire drug development life cycle. This recent funding will significantly bolster Valo's capabilities to accelerate the discovery of life-changing drugs while optimizing costs and minimizing failure rates. The capital raised will primarily be directed towards enhancing the Opal platform, enriching the company's rich pipeline of programs aimed at addressing crucial health concerns such as cardiovascular, metabolic, renal, oncology, and neurodegenerative diseases. With this injection of funds, Valo Health is poised to further its commitment to pioneering drug development methodologies that promise faster, more effective treatments for patients worldwide. As the company embarks on this new chapter of growth, it reaffirms its dedication to bringing transformative therapies to market, thereby improving health outcomes for countless individuals. This funding round not only represents a significant milestone for Valo Health but also highlights the growing recognition of the importance of data-driven approaches in advancing healthcare solutions.
Revolutionizing Drug Discovery: Valo Health Secures $190M in Series A Funding for Innovative AI-Powered Platform
Get the full Valo Health company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Synthetic
We deliver systems, devices and applications that combine the mobility of IoT with the practicality of artificial intelligence. Focusing on high availability connectivity. Our core is based on modular and scalable products for hardware and software solutions.
$10.0M Seed
today
SonoMind
Sonomind is a medical device company specializing in non-invasive brain stimulation utilizing low-intensity focused ultrasound to treat drug-resistant depression and other neurological and psychiatric conditions. This portable device is the first to deliver precision transcranial ultrasound stimulation that is able to penetrate deep brain structures in an accurate, targeted and non-invasive manner. A custom-designed acoustic lens for each patient delivers low-intensity focused ultrasound, enabling ultrasound waves to pass through the skull and compensate for any distortion upon entering the brain. Located in Paris, France, Sonomind has a staff of ten, headed by CEO Jeremy Bercoff. The company leverages 25 years of research undertaken by Profs. Mickael Tanter and Jean-François Aubry at the Institut Physique pour la Médecine (Inserm, ESPCI Paris - PSL, CNRS). Sonomind has raised €2 million since inception
$23.5M Series a
today
.png&w=3840&q=75)
harva. (formerly Supply Pay)
We build the operating system for perishables companies. One platform for inventory, sales, accounting, and embedded financing powered by AI, built for the way perishables actually works. Formerly Supply Pay Inc.
$113.0M Seed
today
Rivermark Medical, Inc.
Minimally Invasive Device Therapy for BPH
$20.0M Series d
today
DDD Invoices - One API, global invoicing compliance
DDD Invoices powers global invoicing compliance in 30+ countries, with a special focus on Central & Eastern Europe. We help SaaS, ERP/POS, PMS, marketplaces, and payment providers integrate mandatory e-invoicing in days — turning compliance from a burden into a competitive advantage. Mandatory e-invoicing is expanding fast — and no company can afford to fall behind. At DDD Invoices, we help software providers embed multi-country e-invoicing and fiscalization directly into their products — in days, not months. With one API, you get: → Compliance in 30+ countries worldwide — including full coverage of CEE mandates (Poland KSeF, Hungary NAV, Romania RO_Cius, Serbia SEF, Croatia Fiscalization 2.0, Montenegro, and more). → Fastest go-live — integrate in days, not months. → Built-in expertise & updates — we track local regulations so you don’t have to. → Monetization potential — turn compliance into a feature your clients will pay for. For ambitious software providers, mandatory e-invoicing is not just a regulatory hurdle — it’s a growth opportunity. DISCOVERY CALL https://calendly.com/ddd-invoices/45min FREE TRIAL https://dddinvoices.com/platform-e-invoicing-invoicing-fiscalization-api LIVE Q&A SESSION, Oct 8 Register on Luma to attend: https://lu.ma/aqtmqw36
$1.5M Seed
today
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | SonoMind | Series a | $23.5M | today |
| 2 |  Raylu United States | Series a | $8.0M | today |
| 3 |  BranchLab United States | Series a | $26.0M | today |
| 4 | .png&w=3840&q=75) SoBanHang (Finan Pte Ltd) Singapore | Series a | $3.8M | today |
| 5 |  Mantle8 France | Series a | $36.6M | 1d ago |